Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by Kusanationon Jul 10, 2020 7:05pm
557 Views
Post# 31254175

Thoughts on Bio Pub

Thoughts on Bio Pub

Seems like they are moving forward. Ultimately Dan said that if they find a good buyer who offers a good deal then he wouldn't mind selling but until then he is moving forward with heading into phase 3. Also, be ready for a reverse split. He made it pretty clear that there will be a reverse split to get us on NASDAQ. He mentioned that the paper work to get on the NASDAQ has been completed and it's only a matter of "when they want to go on it". He also said phase 3 will take about two years after it begins. 


All in all this is going to take a while. He struggled very much answering the question that asked "why should I invest now rather than waiting for the reverse split". This is a little concerning because he couldn't really provide a reason why someone should invest now besides the fact that the stock is undervalued (which is something we already know). 


overall the science is there, it's going to take a while but hopefully he sells this off before. I personally don't think he will. I say this because it seems like he's using it as bare to hang in the face of investors to keep the chasing the idea that can be bought by big pharma. I believe they will be but not pre-phase 3. I think it will happen post phase 3. I can't see him willing to go through getting phase 3 started and working to get on NASDAQ to only then sell it off. But who knows. Thoughts?

Bullboard Posts